Evidence map›Paper›PMID 39451228›Full record

ArticleCells2024

Characterization of Tumor-Infiltrating Lymphocyte-Derived Atypical TCRs Recognizing Breast Cancer in an MR1-Dependent Manner.

Abdul Hayee, Eiji Kobayashi, Chihiro Motozono, Hiroshi Hamana, Ha Thi Viet My, Takuya Okada, Naoki Toyooka, Satoshi Yamaguchi, Tatsuhiko Ozawa, Hiroyuki Kishi

Abstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Abdul HayeeDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama 930-0194, Japan.ORCID 0000-0001-5744-839X
Eiji KobayashiDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama 930-0194, Japan.ORCID 0000-0002-7303-2797
Chihiro MotozonoDivision of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan.ORCID 0000-0002-9027-742X
Hiroshi HamanaDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama 930-0194, Japan.ORCID 0000-0002-6964-1020
Ha Thi Viet MyDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama 930-0194, Japan.
Takuya OkadaDepartment of Biofunctional Molecular Chemistry, Faculty of Engineering, University of Toyama, Toyama 930-8555, Japan.
Naoki ToyookaDepartment of Biofunctional Molecular Chemistry, Faculty of Engineering, University of Toyama, Toyama 930-8555, Japan.ORCID 0000-0002-9568-1528
Satoshi YamaguchiDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama 930-0194, Japan.ORCID 0009-0004-8668-7364
Tatsuhiko OzawaDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama 930-0194, Japan.
Hiroyuki KishiDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama 930-0194, Japan.ORCID 0000-0002-8740-5371

Funding

Japan Society for the Promotion of Science 23H02732Japan Society for the Promotion of Science 24K0232124
6 · The paper itself

Abstract

The MHC class I-related 1 (MR1) molecule is a non-polymorphic antigen-presenting molecule that presents several metabolites to MR1-restricted T cells, including mucosal-associated invariant T (MAIT) cells. MR1 ligands bind to MR1 molecules by forming a Schiff base with the K43 residue of MR1, which induces the folding of MR1 and its reach to the cell surface. An antagonistic MR1 ligand, Ac-6-FP, and the K43A mutation of MR1 are known to inhibit the responses of MR1-restricted T cells. In this study, we analyzed MR1-restricted TCRs obtained from tumor-infiltrating lymphocytes (TILs) from breast cancer patients. They responded to two breast cancer cell lines independently from microbial infection and did not respond to other cancer cell lines or normal breast cells. Interestingly, the reactivity of these TCRs was not inhibited by Ac-6-FP, while it was attenuated by the K43A mutation of MR1. Our findings suggest the existence of a novel class of MR1-restricted TCRs whose antigen is expressed in some breast cancer cells and binds to MR1 depending on the K43 residue of MR1 but without being influenced by Ac-6-FP. This work provides new insight into the physiological roles of MR1 and MR1-restricted T cells.

Indexed as

Breast NeoplasmsHistocompatibility Antigens Class ILymphocytes, Tumor-InfiltratingCell Line, TumorFemaleHumansMinor Histocompatibility AntigensMutationReceptors, Antigen, T-CellHistocompatibility Antigens Class IMinor Histocompatibility AntigensMR1 protein, humanReceptors, Antigen, T-Cellbreast cancerMR1T-cell receptorstumor-infiltrating lymphocytes

Identifiers

PMID39451228
PMCPMC11506377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.